Medtronic RESOLUTE
This article was originally published in The Gray Sheet
Executive Summary
Medtronic initiates a 100-patient, multi-site, first-in-man trial of its Endeavor CR controlled-release, ABT-578-eluting stent in Australia and New Zealand, the firm announces Dec. 13. The stent uses a new slow-release polymer, which could benefit patients with diabetes or complex lesions, the firm says. Medtronic filed its first PMA module for Endeavor in November and expects approval in 2007 (1"The Gray Sheet" Oct. 24, 2005, p. 4)...